RxDoctor Payments Data

Felix Fernandez, DO

Family Medicine · Greeneville, TNNPI 1629017397

Payments from drug & device makers

$4,785in general payments, 2019–2025

Across 295 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$946
  • Novo Nordisk$936
  • Lilly USA, LLC$453
  • Bayer$239
  • Novartis$199
  • Pfizer$179
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,66998%
  • Education$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,785 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$78,820
Medicare patients
195
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide94$124,454
OzempicSemaglutide99$114,254
EliquisApixaban127$97,598
JardianceEmpagliflozin63$75,534
MounjaroTirzepatide60$66,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$44,238
FarxigaDapagliflozin Propanediol48$40,788
KerendiaFinerenone28$26,833
Repatha SureclickEvolocumab19$18,208
EntrestoSacubitril/Valsartan13$17,885
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,553
MyrbetriqMirabegron22$15,344
XareltoRivaroxaban19$13,843
NexlizetBempedoic Acid/Ezetimibe17$10,989
SymbicortBudesonide/Formoterol Fumarate33$10,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$453$191,007154 claims
Novo NordiskOzempic, Levemir$936$118,002114 claims
PfizerEliquis$179$97,598127 claims
Boehringer IngelheimJardiance, Spiriva Respimat$102$83,05074 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$32$67,176102 claims
GSKTrelegy Ellipta$167$44,23865 claims
BayerKerendia$239$26,83328 claims
NovartisEntresto$199$17,88513 claims
Johnson & JohnsonXarelto$64$13,84319 claims
Esperion Therapeutics, Inc.Nexlizet$46$10,98917 claims
AbbVieSynthroid$946$2,15816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →